BMRN

Q: What is the price of BioMarin Pharmaceutical (BMRN) today?

The current price of BioMarin Pharmaceutical (BMRN) is $ 53.81, representing a -15% gain over the past year. The stock began the year trading around $ 59.43 and is currently priced at $ 53.81. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does BioMarin Pharmaceutical (BMRN) pay dividends?

BioMarin Pharmaceutical (BMRN) did not pay dividends over the past year.

BioMarin Pharmaceutical Inc.

Price

$ 53.81

return (12m)

-15.00%

p/e

29.26

p/bv

1.68

DIVIDEND YIELD

0.00%

BMRN price

BMRN

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment BMRN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-0.62%

3 months

-5.36%

1 year

-15.00%

2 years

-33.50%

5 years

-33.13%

10 years

-38.08%

Fundamentals BMRN

review the fundamentals of BioMarin Pharmaceutical shares

P/E

29.26

Sector: -4.04 Industry: -4.04

P/S (PSR)

3.17

Sector: -3.86 Industry: -3.86

P/BV

1.68

Sector: 1.89 Industry: 1.89

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

4.59%

Sector: -61.23% Industry: -61.23%

ROE

5.73%

Sector: -60.44% Industry: -60.44%

ROIC

-3.21%

Sector: -1,165.26% Industry: -1,165.26%

NET MARGIN

10.83%

Sector: -39.16% Industry: -39.16%

GROSS MARGIN

77.73%

Sector: 37.91% Industry: 37.91%

OPERATING MARGIN

12.71%

Sector: -39.32% Industry: -39.32%

EV/EBITDA

17.82

Sector: -3.92 Industry: -3.92

EV/EBIT

20.70

Sector: -4.14 Industry: -4.14

PRICE-TO-ASSETS

1.34

Sector: 1.41 Industry: 1.41

BVPS

31.70

Sector: 1.88 Industry: 1.88

EPS

1.82

Sector: -2.05 Industry: -2.05

EQUITY-TO-ASSETS RATIO

0.80

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

0.20

Sector: 0.39 Industry: 0.39

CAGR REVENUE 5 YEARS

11.78%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF BioMarin Pharmaceutical ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 53.81

Fair Value

$ 0.00

Upside/Downside Return potential.

-33.04%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals BMRN

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	26.05	6.75	25.92%	2.29%	$ 548.05 B	21.83%
PFE	19.76	1.65	8.35%	6.37%	$ 153.52 B	12.42%
ABBV	83.09	0.00	0.00%	3.35%	$ 351.12 B	6.91%
NVO	11.67	6.01	51.50%	4.53%	$ 182.84 B	33.05%
MRK	15.22	0.00	0.00%	2.97%	$ 277.74 B	28.08%
AZN	28.78	6.04	20.99%	1.69%	$ 294.30 B	17.41%
GILD	19.03	7.16	37.62%	2.45%	$ 161.96 B	28.90%
BMY	16.77	-3.48	-20.72%	4.28%	$ 118.31 B	14.64%
ZTS	19.15	15.37	80.25%	1.74%	$ 51.19 B	28.23%
REGN	17.18	2.48	14.41%	0.48%	$ 77.41 B	31.41%
HALO	24.34	158.01	649.21%	0.00%	$ 7.71 B	22.69%
AMGN	24.08	21.45	89.06%	2.80%	$ 185.71 B	20.98%
MCK	23.47	-1,028.86	-4,383.84%	0.38%	$ 101.86 B	1.09%
VRTX	27.65	5.86	21.18%	0.00%	$ 109.29 B	32.94%
HRMY	11.06	2.02	18.24%	0.00%	$ 1.76 B	18.27%
CAH	28.38	-17.47	-61.56%	1.02%	$ 47.16 B	0.68%
ADMA	18.24	5.61	30.78%	0.00%	$ 2.68 B	28.80%
BIIB	20.96	1.48	7.08%	0.00%	$ 27.10 B	13.07%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

BMRN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc.

Average Investor10 user rating

4.0 (3 people)

United States

30 years

Founded: 1996

1999

Time since IPO - 27 years

3.059

Employees

BioMarin Pharmaceutical Inc. (United States) is listed on the Nasdaq and has a market capitalization of $10.21 Billions, with shareholders equity totaling $6.09 Billions.

The company employs approximately 3.059 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, BioMarin Pharmaceutical Inc. reported $3.22 Billions in revenue, generating net income of $348.91 Millions.

Key financial metrics include a P/E ratio of 29.26, a price-to-book (P/B) ratio of 1.68, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BMRN.

Market cap

$ 10.21 Billions

Net worth

$ 6.09 Billions

$ 6,087,000,000.00

Assets

$ 7.59 Billions

$ 7,594,020,000.00

Total Shares Outstanding

192.00 Millions

192,000,000

Average Daily Trading Volume

$ 2.02 Millions

$ 2,023,028.00

Sector

Health Care

Industry

Biotechnology

BMRN

BMRN revenue and profits

Financial Results BMRN

DRAG THE FRAME TO SEE MORE DATA

BMRN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 828.32 18,96% (12M)

P/E

23.47

0.38%

ROE

-4,383.84%

P/BV

-1,028.86

CAH - Cardinal Health

$ 202.34 48,02% (12M)

P/E

28.38

1.02%

ROE

-61.56%

P/BV

-17.47

JNJ - Johnson & Johnson

$ 225.34 49,98% (12M)

P/E

26.05

2.29%

ROE

25.92%

P/BV

6.75

PFE - Pfizer

$ 26.79 26,68% (12M)

P/E

19.76

6.37%

ROE

8.35%

P/BV

1.65

ABBV - AbbVie

$ 197.38 6,86% (12M)

P/E

83.09

3.35%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 110.23 37,32% (12M)

P/E

15.22

2.97%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$ 187.51 33,08% (12M)

P/E

28.78

1.69%

ROE

20.99%

P/BV

6.04

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 828.32 18,96% (12 M)

P/L

23.47

0.38%

ROE

-4,383.84%

P/VP

-1,028.86

CAH - Cardinal Health

$ 202.34 48,02% (12 M)

P/L

28.38

1.02%

ROE

-61.56%

P/VP

-17.47

JNJ - Johnson & Johnson

$ 225.34 49,98% (12 M)

P/L

26.05

2.29%

ROE

25.92%

P/VP

6.75

PFE - Pfizer

$ 26.79 26,68% (12 M)

P/L

19.76

6.37%

ROE

8.35%

P/VP

1.65

ABBV - AbbVie

$ 197.38 6,86% (12 M)

P/L

83.09

3.35%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 110.23 37,32% (12 M)

P/L

15.22

2.97%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 187.51 33,08% (12 M)

P/L

28.78

1.69%

ROE

20.99%

P/VP

6.04

Frequently Asked Questions

What is the price of BioMarin Pharmaceutical (BMRN) today?

The current price of BioMarin Pharmaceutical (BMRN) is $ 53.81, representing a -15% gain over the past year. The stock began the year trading around $ 59.43 and is currently priced at $ 53.81. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does BioMarin Pharmaceutical (BMRN) pay dividends?

BioMarin Pharmaceutical (BMRN) did not pay dividends over the past year.

Is BioMarin Pharmaceutical (BMRN) a good investment?

BioMarin Pharmaceutical (BMRN) is currently trading at $ 53.81 with a P/E ratio of 29.26%. This represents a 7,566% premium compared to its historical average P/E. Over the past year, the stock has gained -15 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -15.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy BioMarin Pharmaceutical (BMRN) stock?

You can buy BioMarin Pharmaceutical (BMRN) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol BMRN and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of BioMarin Pharmaceutical (BMRN) yield today?

Over the past month, BioMarin Pharmaceutical (BMRN) has returned -0.62% — -15.00% over the past year, and -33.13% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of BioMarin Pharmaceutical (BMRN) today at the current price of $ 53.81 your total investment would be $ 5,380.50.

Based on historical performance, the investment would have grown to approximately:

$ 4,573.43 after 1 year
$ 3,597.94 after 5 years
$ 3,331.61 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

BMRN

BioMarin Pharmaceutical Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment BMRN

review the fundamentals of BioMarin Pharmaceutical shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc.

United States

30 years

1999

3.059

PROFIT X PRICE BMRN

Financial Results BMRN

BMRN cash flow

Asset, Revenue and Profit Growth - BMRN

BMRN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions